Stockscreener 앱 받기
1.63
1.24%
0.02
전일 마감가:
$1.61
열려 있는:
$1.635
하루 거래량:
4.73M
Relative Volume:
1.59
시가총액:
$366.31M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.7689
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
-4.68%
1개월 성능:
+5.84%
6개월 성능:
+32.52%
1년 성능:
-11.41%
1일 변동 폭
$1.595
$1.67
1주일 범위
$1.595
$1.84
52주 변동 폭
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.63 | 361.82M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Insider Trends: What are the future prospects of Allogene Therapeutics IncTrade Risk Report & Fast Moving Stock Watchlists - baoquankhu1.vn
Decliners Report: Is AMZE part of any ETF2025 Winners & Losers & Safe Entry Zone Tips - baoquankhu1.vn
Earnings Miss: Is Allogene Therapeutics Inc stock a top momentum play - Bộ Nội Vụ
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sell Signal: What are the risks of holding Allogene Therapeutics Inc2025 Technical Overview & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Earnings Risk: Will Allogene Therapeutics Inc stock hit new highs in YEARJobs Report & Weekly Market Pulse Alerts - baoquankhu1.vn
Allogene Therapeutics Sees Bright Prospects with Upgrades and Awards - StocksToTrade
Allogene Therapeutics Sees Optimistic Outlook as Market Interest Grows - timothysykes.com
Allogene Therapeutics Stock Surges After Promising Market Developments - timothysykes.com
Allogene Therapeutics’ Stock Surges as Analysts Optimistic on Future Outlook - StocksToTrade
Allogene Therapeutics Stock Rises Amid Key Developments - StocksToTrade
Allogene Therapeutics Stock Upgraded as ALPHA3 Trial Inspires Market Confidence - timothysykes.com
Allogene Therapeutics Surges on Positive Analyst Ratings and Arbitration Wins - timothysykes.com
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - sharewise.com
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Citizens Upgrades Allogene Therapeutics (ALLO) - Nasdaq
Allogene Therapeutics (ALLO) Upgraded to Outperform with Significant Upside - GuruFocus
Allogene Therapeutics (ALLO) Upgraded by Citizens to Market Outperform | ALLO Stock News - GuruFocus
Allogene upgraded at Citizens on discounted EPS, revenue multiple - Seeking Alpha
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Citizens Jmp - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to Strong-Buy at UBS Group - MarketBeat
Citizens upgrades Allogene stock rating to Market Outperform on cancer therapy potential - Investing.com
Allogene In Focus: Can ALLO-316 Signal The Breakthrough CAR T Has Been Waiting For In Solid Tumors? - RTTNews
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - Sahm
Why Allogene Therapeutics Inc. stock is favored by pension fundsWeekly Profit Report & Free AI Powered Buy and Sell Recommendations - Улправда
Is Allogene Therapeutics Inc. stock a buy before product launchesRate Hike & Smart Money Movement Tracker - Улправда
Published on: 2026-01-08 23:56:20 - ulpravda.ru
Will Allogene Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Decliners & Fast Gain Stock Trading Tips - Улправда
Can Allogene Therapeutics Inc. stock outperform in 2025 bull market2025 Major Catalysts & Risk Managed Trade Strategies - Улправда
How Allogene Therapeutics Inc. stock reacts to bond yieldsEarnings Growth Report & Consistent Profit Trade Alerts - Улправда
Allogene outlines 2026 clinical milestones for off-the-shelf CAR T - Investing.com India
Allogene Therapeutics interim futility analysis of MRD clearance from phase 2 Alpha3 trial planned for early Q2 2026 - marketscreener.com
Allogene outlines 2026 clinical milestones for off-the-shelf CAR T By Investing.com - Investing.com South Africa
Is Allogene Therapeutics Inc. stock a buy in volatile marketsQuarterly Earnings Review & Access Risk Ratings for Every Stock - Улправда
UBS Initiates Coverage of Allogene Therapeutics (ALLO) with Buy Recommendation - Nasdaq
UBS Initiates Coverage on Allogene Therapeutics (ALLO) with 'Buy' Rating | ALLO Stock News - GuruFocus
UBS initiates coverage on Allogene stock with Buy rating, $8 price target By Investing.com - Investing.com South Africa
UBS initiates coverage on Allogene stock with Buy rating, $8 price target - Investing.com Nigeria
Allogene Therapeutics (NASDAQ:ALLO) Trading 4.4% HigherHere's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Allogene Therapeutics (ALLO) - The Globe and Mail
Is Allogene Therapeutics Inc. stock attractive for growth ETFsQuarterly Growth Report & Real-Time Volume Spike Alerts - Улправда
Why Allogene Therapeutics Inc. stock is seen as undervaluedMarket Activity Recap & Verified Stock Trade Ideas - Улправда
Allogene Therapeutics Earnings Notes - Trefis
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Allogene stock rises after favorable arbitration ruling reaffirms therapy rights By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Solidifies Global Rights to Cema-ce - GuruFocus
Arbitration ruling reaffirms Allogene’s control of cancer therapy By Investing.com - Investing.com Canada
Arbitration ruling reaffirms Allogene’s control of cancer therapy - Investing.com India
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Allogene Therapeutics Inc 주식 (ALLO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Beneski Benjamin Machinas | SVP, Chief Technical Officer |
Nov 17 '25 |
Sale |
1.22 |
786 |
959 |
217,721 |
4.73%
0.92%
자본화:
|
볼륨(24시간):